1 / 33

Focus on Addressing Cognitive Symptoms

Focus on Addressing Cognitive Symptoms. Provided by. In collaboration with. Sponsored by an educational grant from. Program Overview. Part of a 3-component activity for PAs and NPs on achieving sustained remission in MDD Live meetings at AAPA State Chapters and AANP State Organizations

walt
Download Presentation

Focus on Addressing Cognitive Symptoms

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Focus on Addressing Cognitive Symptoms Provided by In collaboration with Sponsored byan educational grant from

  2. Program Overview Part of a 3-component activity for PAs and NPs on achieving sustained remission in MDD • Live meetings at AAPA State Chapters and AANP State Organizations • Three Clinical Case Challenges posted on myCME.com • Print monograph, a supplement to: • JAAPA • The Clinical Advisor

  3. Content Development Faculty • Cindy Parsons, DNP, PMHNP-BC, FAANP • Staff Assistant • Department of Nursing • University of Tampa • Tampa, FL Charles L. Raison, MD Mary Sue and Mike Shannon Chair for Healthy Minds, Children & Families Professor, School of Human Ecology Professor, Department of Psychiatry School of Medicine and Public Health University of Wisconsin Madison, WI Sattaria S. Dilks, DNP, APRN, FAANP Professor and Co-Coordinator Graduate Program College of Nursing McNeese State University Lake Charles, LA

  4. Learning Objectives At the conclusion of this activity, participants will be better able to: • Assess the impact of acute and residual symptoms of cognitive dysfunction in MDD on patient function, quality of life, risk for relapse, and long-term outcomes • Identify patients who might benefit from new pharmacologic treatment options

  5. The Impact of Cognitive Symptoms in MDD

  6. Cognitive Symptoms in MDD • Among the core symptom domains included in the diagnostic criteria for a major depressive episode1 • >30% of patients who otherwise respond to antidepressant therapy report residual cognitive symptoms (forgetfulness, inattentiveness, mental slowing, apathy, and word-finding difficulty)2 • Prevalence: • Among all adults with MDD: 30% - 40%1 • Among MDD patients >65 years: 50% - 60%2 1. Poletti S, et al. J Affect Disord. 2014;156:144-149. 2. Fava M, et al. J Clin Psychiatry. 2006;67:1754-1759.

  7. Cognitive Symptoms in MDD (cont’d) • May predate onset of MDD episode • Distinct neurobiology • Heritable • Some deficits may improve with antidepressant therapy • Differences in antidepressant effects on cognition • Often persist after treatment • Impact quality of life and functional outcomes Trivedi M, Greer TL. J Affect Disord. 2014;152:19-27.

  8. 4 Key Domains of Cognitive Function in MDD The Diagnostic and Statistical Manual of Mental Disorders (5th ed.;DSM–5; American Psychiatric Association [APA], 2013.

  9. Cognitive Symptoms in Measures of Workplace Performance Cognitive Measures Account for More Variability in Workplace Functioning Than Total Depression Severity N=260; HAM-D17 = Hamilton Depression Scale. McIntyre RS, et al. Compr Psychiatry. 2015;56:279-282.

  10. Decline in Gray Matter Volume in Patients with MDD Compared to Healthy Controls • 3-year prospective study comparing 38 patients with 30 healthy controls • Significant decline in gray matter density was noted in the hippocampus, amygdala, ACC, and DMPFC • Threshold was set at P<.001 Frodl TS, et al. Arch Gen Psychiatry. 2008;65:1156-1165.

  11. Association Between Cognitive Function, Disability, and QoL in Patients Treated for Depression Cognitive dysfunction group had significantly greater impairments on the SDS Conclusion: correlation between objectively measured cognitive dysfunction and poorer patient-reported quality of life and disability Kurlander JL, et al. ECNP 2013. Poster P.1.j.006.

  12. Determinants of Cognitive Symptoms in Depression • Patient’s current age/age at onset • Depression severity at onset • Childhood adversity • Level of educational attainment • Frequency/duration of depressive episodes • MDD subtype • Medical/psychiatric comorbidity • Remission status • Treatment McIntyre RS, et al. Compr Psychiatry. 2015;56:279-282.

  13. Measurement of Cognitive Impairment—Clinical Trials • Domains measured/measurement tools utilized vary across trials • Objective testing: neuropsychologic battery • Mini-Mental State Examination, Montreal Cognitive Assessment not sensitive enough for use in MDD • Subjective tests for clinical use • Perceived Deficits Questionnaire (PDQ) • MGH Cognitive and Physical Functioning Questionnaire (CPFQ) • British Columbia Cognitive Complaint Inventory (BC-CCI)

  14. Consistency of Cognitive Impairment in MDD: Meta-analysis • Significant deficits in executive function, memory, and attention • 700 MDD and 700 control subjects (24 studies) • Significant deficits in executive function and attention • 270 unmedicated MDD and 270 controls (8 studies) “Cognitive impairment represents a core feature of depression that cannot be considered an epiphenomenon that is secondary to mood symptoms…” Rock PL, et al. Psychol Med. 2014;44:2029-2040.

  15. Raising the Bar: Evolving Treatment Goals for MDD Cognitive remission 2014 Improved QoL Functional remission ~2010 Improved function Remission ~2000 Response Symptom reduction Before 1990 QoL = quality of life. McIntyre RS. J Clin Psychiatry. 2013;74:14-18.

  16. Strategies for Addressing Cognitive Symptoms in MDD

  17. *Percentages are reported as the remaining percent of those with each symptom at baseline that continued to have the symptom at exit. Response was defined as ≥50% reduction in QIDS-SR16. Presence of symptoms was indicated by a QIDS-SR16 domain score ≥1. McClintock SM, et al. J ClinPsychopharmacol. 2011;31:180-186. What Does Failure to Remit Look Like in Those Who Respond to an Antidepressant? Proportion of responders who had symptoms at baseline that persisted at exit* 81.6 Midnocturnal Insomnia 70.8 Sad Mood 70.6 Concentration/Decision-Making 64.6 Energy 63 Restlessness 60.4 Hypersomnia Sleep-Onset Insomnia 57.5 55 General Interest 49 Early-morning Insomnia 38.9 Negative Self-view Slowed Down 35.6 Increased Weight 35.5 31 Decreased Appetite Increased Appetite 27.8 25.1 Decreased Weight 17.1 Suicidal Ideation

  18. MDD-Related Cognitive Dysfunction Tends to Be Persistent • Up to to 50% of individuals with MDD have a suboptimal therapeutic response1 • Among individuals deemed responsive to antidepressant therapy (n=267), cognitive problems, lack of energy, and sleeping difficulties were present for nearly half the time during remissions (39% to 44%) and most of the time (85% to 94%) during depressive episodes over 3 years of follow-up2 1. Baune BT, et al. Psychiatry Res. 2010;176:183-189. 2. Nierenberg AA, et al. Psychol Med. 2010;40:41-50.

  19. Traditional Antidepressants: Effects on Cognition • Any improvements in cognition were secondary to improvements in mood symptoms • To date, no conventional antidepressant has shown significant improvements in cognitive symptoms • MDD patients who achieve remission of other symptoms often have persistent cognitive deficits • Some antidepressants worsen cognitive deficits • Study limitations: small sample sizes; lack of replication; not always placebo-controlled; cognitive function not primary endpoint; largest studies conducted in the elderly, or in populations with large age range McIntyre RS, et al. Depress Anxiety. 2013;30:515-527; Fava M, et al. J Clin Psychiatry. 2006;67:1754-1759;Greer TL, et al. CNS Drugs. 2010;24:267-284; Herrera-Guzman I. J Affect Disord. 2010;123:341-350; McClintock SM, et al. J Clin Psychopharmacol. 2011;31:180-186; Trivedi MH, Daly EJ. Dialogues Clin Neurosci. 2008;10:377-384; Millan MJ, et al. Nat Rev Drug Discov. 2012;11:141-168.

  20. New Multimodal Antidepressants Reuptake inhibitors + 5-HT receptor actions to add to the efficacy and/or reduce adverse effects 5-HT3 5-HT1A 5-HT1A Vilazodone Vortioxetine 5-HT1B 5-HT10 SERT SERT 5-HT7 Other multimodal drugs in development: brexpiprazole, amitifadine SERT = serotonin transporter. Nutt DJ. J Psychopharmacol. 2009;23;343-345.Richelson E. Int J Neuropharmacol. 2013;16:1433-1442.Mork A, et al. ENCP 2013. Poster P.2.e.002.

  21. Vortioxetine Effect on Cognitive Performance Primary end point: composite z-score (DSST / RAVLTacq / RAVLTdelay) at Week 8 vs placebo (FAS, MMRM) NCT01422213 *P<.001; †P<.05; ‡P<.01; vs placebo. DSST = Digit Symbol Substitution Test; RAVLT = Rey Auditory Verbal Learning Test; acq = acquisition; delay = delayed recall; FAS = full analysis set; MMRM = mixed model for repeated measurements. *Vortioxetine is not FDA approved for treatment of cognitive impairment. McIntyre RS, et al. Int J Neuropsychopharmacol. 2014;17:1557-1567.

  22. Preclinical Comparison of Vortioxetine, SSRIs, and SNRIs in Cognitive Function Study Assessed Cognitive Function Using Quantitative EEG Measurers and a Novel Object Recognition Memory Task in Normal and 5-HT-Depleted Rats Episodic Memory (novel object recognition test) Spatial Memory (spontaneous alteration) § § Preference Score (%) Alteration (%) PCPA PCPA Control Control Duloxetine Duloxetine Vortioxetine Vortioxetine Escitalopram Escitalopram Occupancy (%) SERT 88 >90 95 *P<.05, †P<.01, ‡P<.001 vs control; §P<.05 vs PCPA • Vortioxetine restored memory deficits induced by 5-HT depletion; escitalopram and duloxetine did not • Results suggest a role for vortioxetine in modulating cortical networks recruited during cognitive behavior EEG = electroencephalography; PCPA = 4-chloro-DL-phenylalanine Mork A, et al. ECNP 2013. Poster P.2.e.002.

  23. Long-term Safety and Tolerability of Vortioxetine 52-Week, Long-term, Open-Label, Flexible-Dose Extension Study of Vortioxetine 15 or 20 mg/day TEAEs reported by at least 5 patients (N=71) Similar long-term adverse event profile to that observed during short-term treatment TEAEs = treatment-emergent adverse events. Filippov G, et al. ENCP 2013. Poster P.2.b.011.

  24. Frampton JE. CNS Drugs. 2011;25:615-627. Safety and Tolerability of Vilazodone 30 Vilazodone(n=436) 25 Placebo (n=433) 20 Incidence (% of patients) 15 10 5 0 Fatigue Nausea Anxiety Diarrhea Vomiting Dizziness Insomnia BackPain Headache DryMouth Somnolence Nasopharyngitis Weight Increased Abnormal Dreams Increased Appetite Upper Respiratory Tract Infection Short-term tolerability of oral vilazodone in adult patients with MDD.Incidence of treatment-emergent adverse events occurring in ≥5% of vilazodone patients.40-mg, once-daily recipients in two 8-week, double-blind, placebo-controlled studies (pooled results).

  25. Investigational Compounds With Potential Procognitive Effect • Modafinil • Considered an effective augmentation strategy for both acute unipolar or bipolar depressive episodes1 • 4-week, open-label study in 35 patients with a history of MDD2 • Partial response of depressive symptoms; some improvement of cognitive function • Donepezil • Available evidence to date does not suggest a clear benefit as adjunctive therapy to antidepressants for cognitive enhancement3 • Clinical trial to assess cognitive improvement for a large sample of cognitively impaired MDD patients with combined treatment of antidepressant/donepezil is ongoing 1. Goss AJ, et al. J Clin Psychiatry. 2013;74:1101-1107. 2. DeBattista C, et al. J Clin Psychopharmacol. 2004;24:87-90.3. Reynolds CF 3rd. Arch Gen Psychiatry. 2011;68:51-60.

  26. Investigational Compounds With Potential Procognitive Effect (cont’d) • Ketamine • May have neuroprotective effects, including in an ECT treatment context1,2 • Additional clinical trials are ongoing • S-adenosyl-methionine (SAME-E) • Superior to placebo and comparable to tricyclic antidepressants for MDD symptoms3 • Preliminary evidence shows improved recall information and a trend toward a greater enhancement in word-finding in depressed patients treated with oral, adjunctive SAM-E4 1. Hudetz JA, Pagel PS. J CardiothoracVascAnesth. 2010;24:131-142.  2. MacPherson RD, Loo CK. J ECT. 2008;24:52-56. 3. Papakostas GI, et al. J Clin Psychiatry. 2009;70(suppl 5):18-22. 4. Levkovitz Y, et al. Eur Psychiatry. 2012;27:518-521.

  27. Investigational Compounds With Potential Procognitive Effect (cont’d) • Erythropoietin (EPO) • Single high dose may enhance memory/executive function1 • Follow-up, randomized, double-blind, placebo-controlled study: sustained improvements in verbal learning and memory after repeated EPO administrations as adjunctive treatment (8 weekly infusions of 1 ml recombinant EPO—doses of 40,000 UI) versus placebo2 in patients with TRD • Lisdexamfetamine (LDX) • Randomized, double-blind, placebo-controlled, parallel-group study for treating executive dysfunction in patients on antidepressant therapy with full or partial remission of other symptoms • In addition to improvement of any residual depressive symptomatology, patients treated with LDX displayed greater executive improvement compared with placebo 1. Miskowiak  KW, et al. Psychopharmacology (Berl). 2012;219:687-698. 2. Miskowiak KW, et al. Biol Psychiatry. 2014 Dec 18. 3. Madhoo M, et al. Neuropsychopharmacology. 2014;39:1388-1398.

  28. Alternative Therapeutic Strategies to Address Cognitive Symptoms ↑ = improvement; ↓ = worsening; ± = no marked change. Millan ML, et al. Nat Rev Drug Discov. 2012;11:141-168.

  29. Targeting Cognitive Deficits in MDD: Cognitive Remediation • Potential aim: to exercise specific pathways with the goal of remediating specific areas of cognitive function • Methods: using behavioral strategies to improve a range of neuropsychologic domains, such as memory and executive functioning • Techniques: cognitive control training sessions, computer games, group discussion, homework, application to real-life situations Bowie CR, et al. J NervMent Dis. 2013;201:680-685.

  30. Trivedi MH. J Clin Psychiatry. 2009;70(suppl 6):26-31. American Psychiatric Association. http://psychiatryonline.org/data/Books/prac/PG_Depression3rdEd.pdf. Accessed March 30, 2015. Measurement-Based Care for MDD • Systematically use measurement tools to monitor progress and guide treatment choices • Regularly scheduled visits • Time-efficient, validated tools • Regularly monitoring symptom improvement, side effects, medication adherence • Use a treatment algorithm with established critical decision points

  31. HRSD = Hamilton Rating Scale for Depression. Geerts E, et al. J Affect Disord. 1996;40:15-21. Krupnick JL, et al. J Consult Clin Psychol. 1996;64:532-539. Establishing a Therapeutic Alliance Early inTreatment Is a Powerful Remission Tool 35 Β=.46, P=.009 30 25 20 Improvement (HRSD T1–T2) 15 10 5 0 -5 -0.5 1.0 -1.0 0.0 0.5 -1.5 Change of Attunement During First Clinical Interview

  32. Summary • Cognitive symptoms of MDD are especially difficult to treat and frequently persist even when patients are otherwise responsive to an antidepressant • Traditional antidepressants frequently failed to adequately address cognition • New multimodal antidepressants appear to be particularly efficacious in targeting the residual symptoms of MDD, particularly in regard to cognitive deficits, with favorable side-effect profiles • However, not all patients may be candidates for these therapies; individualization of therapy is key

  33. Summary (cont’d) • Alternative approaches—especially cognitive therapy—may be helpful • The goal of MDD remains: remission of all symptoms, including cognition • It is critical to continuously monitor therapeutic response and make adjustments accordingly • A number of validated instruments have been developed to facilitate monitoring of response • As with any chronic disease, the patient-provider relationship is paramount for good outcomes

More Related